Firm expects the platform will help overcome previous challenge of supplying sufficient rBChE.
PharmAthene gained expanded access to GTC Biotherapeutics’ patent rights to support its prophylactic and therapeutic against chemical nerve agents. Protexia® is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats.
This license agreement gives PharmAthene access to GTC’s transgenic technology, which will aid PharmAthene in the development, manufacture, regulatory approval, and commercialization of Protexia. PharmAthene is confident that transgenic production and manufacturing will overcome previous limitations of producing commercial quantities. The company predicts that it will be capable of supplying sufficient rBChE to make Protexia available for use by the military and civilian populations.
This expanded license agreement follows the recently announced deal under which GTC is providing PharmAthene clinical supply and manufacturing services for Protexia.
